324 related articles for article (PubMed ID: 24158761)
1. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point.
Bachman E; Travison TG; Basaria S; Davda MN; Guo W; Li M; Connor Westfall J; Bae H; Gordeuk V; Bhasin S
J Gerontol A Biol Sci Med Sci; 2014 Jun; 69(6):725-35. PubMed ID: 24158761
[TBL] [Abstract][Full Text] [Related]
2. Testosterone Administration During Energy Deficit Suppresses Hepcidin and Increases Iron Availability for Erythropoiesis.
Hennigar SR; Berryman CE; Harris MN; Karl JP; Lieberman HR; McClung JP; Rood JC; Pasiakos SM
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31894236
[TBL] [Abstract][Full Text] [Related]
3. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
4. Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.
Dhindsa S; Ghanim H; Batra M; Kuhadiya ND; Abuaysheh S; Green K; Makdissi A; Chaudhuri A; Dandona P
Clin Endocrinol (Oxf); 2016 Nov; 85(5):772-780. PubMed ID: 27292585
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer.
Gagliano-Jucá T; Pencina KM; Ganz T; Travison TG; Kantoff PW; Nguyen PL; Taplin ME; Kibel AS; Li Z; Huang G; Edwards RR; Nemeth E; Basaria S
Am J Physiol Endocrinol Metab; 2018 Dec; 315(6):E1185-E1193. PubMed ID: 30325657
[TBL] [Abstract][Full Text] [Related]
6. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.
Coviello AD; Kaplan B; Lakshman KM; Chen T; Singh AB; Bhasin S
J Clin Endocrinol Metab; 2008 Mar; 93(3):914-9. PubMed ID: 18160461
[TBL] [Abstract][Full Text] [Related]
7. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells.
Guo W; Bachman E; Li M; Roy CN; Blusztajn J; Wong S; Chan SY; Serra C; Jasuja R; Travison TG; Muckenthaler MU; Nemeth E; Bhasin S
Aging Cell; 2013 Apr; 12(2):280-91. PubMed ID: 23399021
[TBL] [Abstract][Full Text] [Related]
8. Vitamin A supplementation in children with poor vitamin A and iron status increases erythropoietin and hemoglobin concentrations without changing total body iron.
Zimmermann MB; Biebinger R; Rohner F; Dib A; Zeder C; Hurrell RF; Chaouki N
Am J Clin Nutr; 2006 Sep; 84(3):580-6. PubMed ID: 16960172
[TBL] [Abstract][Full Text] [Related]
9. Hepcidin is not essential for mediating testosterone's effects on erythropoiesis.
Guo W; Schmidt PJ; Fleming MD; Bhasin S
Andrology; 2020 Jan; 8(1):82-90. PubMed ID: 31001931
[TBL] [Abstract][Full Text] [Related]
10. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis.
Bachman E; Feng R; Travison T; Li M; Olbina G; Ostland V; Ulloor J; Zhang A; Basaria S; Ganz T; Westerman M; Bhasin S
J Clin Endocrinol Metab; 2010 Oct; 95(10):4743-7. PubMed ID: 20660052
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.
Ghanim H; Abuaysheh S; Hejna J; Green K; Batra M; Makdissi A; Chaudhuri A; Dandona P
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32044999
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin as a potential biomarker for blood doping.
Leuenberger N; Bulla E; Salamin O; Nicoli R; Robinson N; Baume N; Saugy M
Drug Test Anal; 2017 Jul; 9(7):1093-1097. PubMed ID: 27758046
[TBL] [Abstract][Full Text] [Related]
13. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
14. Decreased plasma soluble erythropoietin receptor in high-altitude excessive erythrocytosis and Chronic Mountain Sickness.
Villafuerte FC; Macarlupú JL; Anza-Ramírez C; Corrales-Melgar D; Vizcardo-Galindo G; Corante N; León-Velarde F
J Appl Physiol (1985); 2014 Dec; 117(11):1356-62. PubMed ID: 25324511
[TBL] [Abstract][Full Text] [Related]
15. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
16. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
[TBL] [Abstract][Full Text] [Related]
18. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711
[TBL] [Abstract][Full Text] [Related]
19. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
20. Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor.
Kralova B; Sochorcova L; Song J; Jahoda O; Hlusickova Kapralova K; Prchal JT; Divoky V; Horvathova M
Am J Hematol; 2022 Oct; 97(10):1286-1299. PubMed ID: 35815815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
